Table 3.

Details of exclusion reasons.

First author, year	The exclusion reasons
Rimola A, 200427	Not RCT. The results were demonstrated by percentage of cirrhosis or mean and range of cirrhosis but not mean ± SD which could not be calculated with other studies in the meta-analysis.
Rincon D, 200537	Not RCT. The results were demonstrated by percentage of fibrosis stage 2–4 but not mean ± SD which could not be calculated with other studies in the meta-analysis.
Sookoian S, 200529	Not RCT. The basic fibrosis was not comparable between the two groups.
Yoshiji H, 200538	The treated group was given both IFN and perindopril while the controlled group treated nothing.
Yoshiji H, 200639	The results were demonstrated by changed percentage of fibrosis score which could not be calculated with other studies in the meta-analysis.
Corey KE, 200928	Not RCT. The results were demonstrated by mean of cirrhosis without SD which could not be calculated with other studies in the meta-analysis.
Colmenero J, 200941	Not RCT. No control group.
Cholongitas E, 201042	Not RCT. The results were demonstrated by changed mean fibrosis score but not mean ± SD which could not be calculated with other studies in the meta-analysis.
Abu Dayyeh BK, 201132	The results were demonstrated by percentage of 2-point increases in fibrosis which could not be calculated with other studies in the meta-analysis.
Yoshiji H, 201231	The treated group was given both IFN and perindopril while the controlled group treated nothing.
Guillaud O, 201345	Not RCT. The results were demonstrated by change of median fibrosis score which could not be calculated with other studies in the meta-analysis.

RCT, randomized controlled trial; SD, standard deviation; IFN, interferon.